AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
We have 3 of 272 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Pirtobrutinib and CAR T-cell therapy and CAR T-cell therapy have emerged as effective treatment options for refractory or progressive disease after prior treatment with covalent BTK inhibitors.
This retrospective observational study characterizes R‐GemOx treatment patterns and outcomes among patients with R/R LBCL from the nationwide, longitudinal Flatiron Health electronic health record‐derived database comprising patient‐level data primarily from US community oncology practices.
CD123-directed CAR T-cell therapy is feasible and demonstrates a favorable safety profile in patients with r/r AML and BPDCN, including those with prior alloHCT, according to a phase 1 trial evaluating CD123-targeting chimeric antigen receptor (CAR) T cells in patients with relapsed/refractory AML.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.